18F-Fluoromisonidazole in tumor hypoxia imaging

Zuoyu Xu; Xiao-Feng Li; Hongyan Zou; Xilin Sun; Baozhong Shen

doi:10.18632/oncotarget.21662

¹⁸F-Fluoromisonidazole in tumor hypoxia imaging

Oncotarget. 2017 Oct 7;8(55):94969-94979. doi: 10.18632/oncotarget.21662. eCollection 2017 Nov 7.

Authors

Zuoyu Xu^{1

2}, Xiao-Feng Li^{1

2}, Hongyan Zou¹, Xilin Sun^{1

2}, Baozhong Shen^{1

2}

Affiliations

¹ Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China.
² TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

Abstract

Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. ¹⁸F-Fluoromisonidazole positron emission tomography (¹⁸F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between ¹⁸F-FMISO PET and other detection methods, current applications of ¹⁸F-FMISO PET and the development prospects of this imaging technology.

Keywords: 18F-Fluoromisonidazole; PET; hypoxia; tumor.

Publication types

Review